ResMed stock (US7611521078): sleep apnea specialist in focus after latest quarterly results

ResMed shares remain in focus after the company reported its latest quarterly results and updated investors on demand trends for sleep apnea devices and masks. The sleep health specialist continues to navigate competitive and reimbursement dynamics that are closely watched by US investors.

ResMed reported results for its fiscal third quarter ended March 31, 2026, showing continued revenue growth driven by strong demand for sleep apnea devices, masks and related software, according to a company earnings release published on April 24, 2026 on its investor relations site ResMed investor update as of 04/24/2026. The company also discussed market trends in sleep and respiratory care, including the impact of competition and reimbursement, as reported by financial media on the same day Reuters coverage as of 04/24/2026.

As of: 05/20/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ResMed Inc.
• Sector/industry: Medical technology / sleep and respiratory care
• Headquarters/country: San Diego, United States
• Core markets: Sleep apnea therapy, respiratory care, cloud-connected devices and software
• Key revenue drivers: Sleep apnea devices, masks and accessories, cloud software and data services for providers
• Home exchange/listing venue: New York Stock Exchange (ticker: RMD)
• Trading currency: US dollar (USD)

ResMed: core business model

ResMed focuses on medical devices and digital health solutions for treating sleep apnea and other chronic respiratory conditions. The company designs and manufactures positive airway pressure devices, masks and accessories used primarily at home by patients with obstructive sleep apnea. These products are typically prescribed by physicians and supplied through durable medical equipment providers, which connect ResMed to both public and private payers.

In addition to hardware, ResMed has built a digital health platform that connects millions of devices to the cloud. This connectivity allows remote monitoring of patient adherence and therapy effectiveness, and supports data-driven workflows for home medical equipment providers and sleep labs. Management regularly highlights the importance of recurring revenue from masks, accessories and software subscriptions alongside new device placements, according to company presentations and filings released with recent quarterly reports ResMed investor materials as of 04/24/2026.

ResMed’s business model is therefore a combination of capital equipment and recurring consumables and services. Devices generate an installed base, which in turn supports ongoing demand for masks, tubing, filters and related items that need regular replacement. On top of that, software and data platforms provide digital tools that help providers manage patient populations, document adherence and navigate reimbursement requirements in the United States and other markets.

Main revenue and product drivers for ResMed

ResMed’s revenue is broadly split between its sleep and respiratory care segment and its software-as-a-service offerings for out-of-hospital care. Within sleep and respiratory care, continuous positive airway pressure devices and bilevel devices are central. New device shipments depend on factors such as physician diagnosis rates, payer coverage policies, and replacement cycles when older equipment is retired. The company has also historically benefited from competitor supply disruptions in certain periods, which shifted demand to ResMed, according to past commentary accompanying financial results ResMed results commentary as of 10/26/2023.

Masks and accessories form another major revenue stream. Once a patient starts on therapy, they typically need periodic replacement of masks, cushions and other components. This consumables demand can lead to relatively stable, recurring revenue that is less volatile than initial device orders. The extent of this recurring stream depends on how well patients adhere to therapy and on payer rules for replacement intervals in each market. ResMed’s cloud connectivity aims to support adherence by allowing clinicians and providers to monitor use and intervene when patients struggle with treatment.

Beyond hardware, ResMed owns software platforms that support out-of-hospital care settings, including home health, hospice and senior living. These solutions help providers manage clinical documentation, billing and regulatory compliance. While these software businesses represent a smaller share of total revenue compared with devices and masks, they generally follow a subscription model, which can contribute to revenue visibility and margin stability over time, as noted in previous annual reports where the company has broken out segment performance ResMed annual filing as of 08/17/2023.

Industry trends and competitive position

The global market for sleep apnea diagnosis and treatment has expanded as awareness of sleep disorders increases and links to cardiovascular and metabolic diseases become better known. In the United States, a large pool of undiagnosed patients continues to represent potential long-term demand. However, diagnosis trends can fluctuate with changes in referral patterns, access to sleep labs and home sleep testing protocols. Companies such as ResMed and its main peers compete for device placements and mask preference among clinicians and patients.

ResMed’s competitive position has been influenced by product innovation, cloud connectivity and the reliability of its supply chain. Over recent years, the company has emphasized small, quiet devices and user-friendly mask designs, aiming to support patient comfort and adherence. Connectivity features allow automatic data transmission, which can reduce administrative burdens for providers and help verify usage for reimbursement. This digital layer creates switching costs for providers integrated into ResMed’s ecosystem, according to descriptions in company marketing materials and investor presentations ResMed presentation as of 03/12/2024.

Competitive dynamics can be affected by regulatory actions, product recalls and pricing pressures. Past industry events, such as safety-related recalls by competitors, have temporarily changed market share patterns and price negotiations. Reimbursement rules from Medicare, private insurers and international health systems also shape pricing and volumes. For ResMed, the ability to manage these external factors while continuing to innovate remains a central theme for investors monitoring the stock.

Why ResMed matters for US investors

For US investors, ResMed is part of the domestic medical technology landscape and is listed on the New York Stock Exchange, providing straightforward access through US brokerage accounts. The company’s revenue exposure is diversified geographically, but the United States remains a significant market because of its large population of patients with sleep apnea and chronic respiratory conditions. Reimbursement decisions from US payers, including Medicare and major private insurers, therefore directly influence the company’s performance.

ResMed is also linked to long-term trends such as aging populations, rising obesity rates and a growing focus on home-based care. These structural drivers tend to support demand for sleep apnea therapy and remote patient monitoring tools over multi-year horizons. At the same time, US investors often monitor shorter-term catalysts like quarterly earnings, guidance updates and any changes in competitive dynamics. For example, commentary on device demand, mask replacement trends and software growth within the United States can shape expectations for future revenue and margin profiles, as highlighted in recent earnings calls and presentations accompanying quarterly updates ResMed earnings call materials as of 01/25/2024.

Another element for US-focused portfolios is ResMed’s role as a specialized player rather than a diversified conglomerate. This specialization can offer targeted exposure to the sleep and respiratory care segment of the health care market. Investors who track the sector often compare ResMed’s growth, profitability and cash flow metrics with broader medtech and health care indices, as well as with other device manufacturers. Positioning within these benchmarks and ETFs can influence trading volumes and index-related flows into the stock.

Conclusion

ResMed remains a key name in sleep and respiratory care, combining medical devices, recurring consumables and cloud-based software. Recent quarterly results underscored ongoing demand for sleep apnea therapy and highlighted the importance of connectivity and data for supporting patient adherence and payer requirements. At the same time, the company operates in a competitive environment shaped by reimbursement policies, technology innovation and rival manufacturers. For US investors, ResMed offers focused exposure to structural health care trends related to sleep disorders and home-based care, but performance will continue to depend on how effectively management executes on growth opportunities while navigating regulatory and competitive pressures.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.